Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The Company operates in Japan and overseas.

Employees

5,669

Sector

Pharmaceuticals

Calendar

07-31 - Q2 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-07-18	2,523.00 ¥	-0.51%	822,300
25-07-17	2,536.00 ¥	+1.66%	754,400
25-07-16	2,494.50 ¥	+0.63%	524,000
25-07-15	2,479.00 ¥	+0.16%	811,500
25-07-14	2,475.00 ¥	-0.20%	491,800

Delayed Quote Japan Exchange, July 18, 2025 at 02:30 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2,536.00JPY

Average target price

2,515.00JPY

Spread / Average Target

-0.83%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Japan Exchange Other stock markets 02:30:00 2025-07-18 EDT			5-day change	1st Jan Change
2,523.00 ^JPY	-0.51%		+1.73%	+6.21%

07-01	Kura Oncology, Inc. and Kyowa Kirin, Inc. Enter into A Co-Promotion and Medical Affairs Agreement	CI
06-24	Nektar's lead drug candidate shows promise in eczema trial, shares soar	RE

Capitalization	1,327B 8.94B 7.71B 7.19B 6.66B 12.29B 769B 13.79B 87.18B 32.82B 360B 33.52B 32.83B	P/E ratio 2025 *	23.8x	P/E ratio 2026 *	20.1x
Enterprise value	1,091B 7.35B 6.34B 5.91B 5.48B 10.1B 632B 11.33B 71.65B 26.98B 296B 27.55B 26.98B	EV / Sales 2025 *	2.29x	EV / Sales 2026 *	2.15x
Free-Float	41.96%	Yield 2025 *	2.37%	Yield 2026 *	2.45%

Kura Oncology, Inc. and Kyowa Kirin, Inc. Enter into A Co-Promotion and Medical Affairs Agreement	07-01	CI
Nektar's lead drug candidate shows promise in eczema trial, shares soar	06-24	RE
Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress	06-12	CI
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia	06-12	MT
SMBC Nikko Upgrades Kyowa Kirin to Outperform from Neutral; Price Target is 2,900 Yen	06-04	MT
Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. Report Positive Pivotal Ziftomenib Monotherapy Data At 2025 ASCO Annual Meeting	06-03	CI
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data	06-02	RE
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory Npm1-Mutant Aml	06-02	CI
Kura Oncology, Kyowa Get FDA Acceptance, Priority Review of New Drug Application for Ziftomenib	06-02	MT
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation At the 2025 European Hematology Association Congress	05-14	CI
Japan's Nikkei snaps 7-day winning streak as US tariff worries weigh	05-07	RE
Kyowa Kirin to Dispose of Treasury Shares for Executive Compensation	03-20	MT
Amgen and Kyowa Kirin Co., Ltd. Provide Top-Line Results from Roccatinlimab Phase 3 Initiative Study in Results with Moderate to Severe Atopic Dermatitis	03-08	CI

SMBC Nikko Upgrades Kyowa Kirin to Outperform from Neutral; Price Target is 2,900 Yen	06-04	MT
Jefferies Adjusts Kyowa Kirin's Price Target to 2,500 Yen From 3,000 Yen, Keeps at Buy	03-07	MT
Jefferies Adjusts Kyowa Kirin's Price Target to 3,000 Yen From 3,700 Yen, Keeps at Buy	11-22	MT
Jefferies Adjusts Kyowa Kirin's Price Target to 3,700 Yen From 3000 Yen, Keeps at Buy	24-08-05	MT
Jefferies Adjusts Kyowa Kirin’s Price Target to 3,000 Yen From 3,600 Yen, Keeps at Buy	23-10-09	MT

Kyowa Kirin Co., Ltd. Stock

Equities

4151

JP3256000005

Pharmaceuticals

Valuation: Kyowa Kirin Co., Ltd.

Chart: Kyowa Kirin Co., Ltd.

Latest news: Kyowa Kirin Co., Ltd.

Analysts' recommendations: Kyowa Kirin Co., Ltd.

Press Releases: Kyowa Kirin Co., Ltd.

News in other languages: Kyowa Kirin Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Kyowa Kirin Co., Ltd.

ETFs: Kyowa Kirin Co., Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Kyowa Kirin : Announces Approval for Additional Formulation of “LUMICEF® Subcutaneous Injection 210 mg Pen” in Japan	06-26	PU
Kyowa Kirin : Received Approval in Japan for Prefilled Syringe Formulation of CrysvitaⓇ	06-25	PU
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress	06-12	AQ
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML	06-01	AQ
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting	05-22	AQ

Rally di quattro sedute del Nikkei si interrompe su prese profitto	24-09-25
DKSH erhält Auftrag von Kyowa Kirin aus Japan	24-08-02
EEUU aprueba la primera terapia de genes para niños con una rara enfermedad hereditaria	24-03-18
MÄRKTE ASIEN/Tokio sehr fest auf 34-Jahreshoch - Softbank mit Kurssprung	24-02-08
Kyowa Kirin schließt erfolgreich die Übernahme von Orchard Therapeutics ab, einem Weltmarktführer für Gentherapie bei seltenen Krankheiten	24-01-24

1 day	-0.51%
1 week	+1.73%
Current month	+2.33%
1 month	+1.28%
3 months	+14.47%
6 months	+9.98%
Current year	+6.21%

1 week	2,465	2,540
1 month	2,400	2,540
Current year	2,025	2,540
1 year	2,025	3,350
3 years	2,025	3,515
5 years	2,025	4,240
10 years	1,412	4,240

Manager	Title	Age	Since
Masashi Miyamoto CEO	Chief Executive Officer	66	-
Abdul Mullick PSD	President	-	2025-03-27
Motohiko Kawaguchi DFI	Director of Finance/CFO	-	1986-03-31

Director	Title	Age	Since
Masashi Miyamoto CHM	Chairman	66	2025-03-27
Akira Morita BRD	Director/Board Member	74	2019-02-28
Takeshi Minakata BRD	Director/Board Member	63	2022-03-29

Name	Weight	AuM	1st Jan change
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY	2.22%	28 M€	-7.97%	-
OSSIAM WORLD ESG MACHINE LEARNING UCITS ETF 1A - EUR	1.51%	0 M€	-.--%	-
GLOBAL X MSCI GOVERNANCE-QUALITY JAPAN ETF - JPY	0.44%	5 M€	+1.32%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
KYOWA KIRIN CO., LTD.	-0.51%	+1.73%	-20.28%	-19.90%	8.94B
MERCK KGAA	+0.13%	-0.98%	-26.78%	-32.45%	56.21B
YUHAN CORPORATION	+20.50%	+21.14%	+40.58%	+161.29%	7.3B
HALOZYME THERAPEUTICS, INC.	-0.35%	+0.30%	+5.58%	+17.59%	7.12B
SK BIOPHARMACEUTICALS CO., LTD.	+5.74%	+4.14%	+21.15%	+32.01%	5.8B
BETTA PHARMACEUTICALS CO., LTD.	+0.39%	+6.20%	+93.66%	+12.77%	3.58B
SUPERNUS PHARMACEUTICALS, INC.	+0.21%	+1.36%	+16.03%	+13.17%	2.1B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+0.09%	+1.46%	-9.87%	+20.69%	2.08B
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.	+0.57%	+7.13%	+101.27%	+45.05%	1.99B
INDIVIOR PLC	+1.87%	+4.47%	+47.38%	-21.97%	1.97B
Average	+2.87%	+4.21%	+26.87%	+22.82%	9.71B
Weighted average by Cap.	+2.01%	+1.08%	-6.02%	-3.61%

	2025 *	2026 *
Net sales	476B 3.21B 2.77B 2.58B 2.39B 4.41B 276B 4.94B 31.27B 11.77B 129B 12.02B 11.78B	498B 3.35B 2.89B 2.7B 2.5B 4.61B 288B 5.17B 32.69B 12.31B 135B 12.57B 12.31B
Net income	56.2B 378M 327M 305M 282M 520M 32.56B 584M 3.69B 1.39B 15.24B 1.42B 1.39B	66.35B 447M 386M 360M 333M 614M 38.44B 689M 4.36B 1.64B 18B 1.68B 1.64B
Net Debt	-236B -1.59B -1.37B -1.28B -1.19B -2.19B -137B -2.46B -15.53B -5.85B -64.13B -5.97B -5.85B	-256B -1.72B -1.49B -1.39B -1.28B -2.37B -148B -2.66B -16.8B -6.33B -69.39B -6.46B -6.33B